This piece looks at why billionaire Tom Steyer and other big investors are watching Liquidia Corporation (LQDA), focusing on institutional buying patterns, the rapid market adoption of its inhaled treprostinil product, the legal headwinds it faces, and the commercial milestones that could reshape the company’s valuation.
Liquidia first popped up in hedge fund filings back in mid-2020 and then vanished from those pages later that year, only to reappear as a fresh position in 2024. One prominent fund rebuilt a stake that swelled to millions of shares by the end of 2025, signaling renewed conviction from institutional desks. That pattern — exit, re-entry, and accumulation — is a common play when investors see a clearer path to commercialization and scale.
The company is best known for advancing treatments in rare cardiopulmonary conditions, with a narrow but valuable focus on pulmonary hypertension. That therapy concentration gives Liquidia a defined commercial runway and a small pool of prescribers to target, which can accelerate market penetration if execution is crisp. In specialty markets, a tight sales pitch and strong clinical data often beat broad diversification.
Liquidia’s headline driver right now is YUTREPIA, a dry-powder formulation of treprostinil. The company reported quarterly product sales that jumped meaningfully quarter over quarter, and since YUTREPIA’s full launch the product has taken a notable slice of the inhaled treprostinil market. Rapid uptake in a short window is a bullish signal for investors betting on durable demand and improved economics for the company.
That bullish case is tempered by an active legal battle with a larger rival, which remains a material risk for investors to watch. Patent disputes and litigation can delay rollouts, constrain distribution, or siphon cash through legal fees, so outcomes in the courts could change the risk-reward math quickly. Even with strong sales momentum, the company is not immune to setbacks tied to intellectual property rulings.
Despite those risks, several hedge funds and high-profile investors are positioning for upside as Liquidia scales its commercial footprint. The company has been beefing up its sales organization and engaging hundreds of active prescribers, moves that suggest management expects continued adoption. Leadership has presented a pathway to hitting a billion-dollar franchise level within a relatively short timeframe if trends hold.
From an investor’s standpoint, Liquidia offers a mix of high-reward and high-uncertainty elements: robust early sales, a focused market opportunity, and litigation that could swing valuation both ways. Those weighing the stock should watch a handful of catalysts closely — quarterly revenue cadence, prescriber expansion, reimbursement trends, and legal developments. Each of these will be a clear touchpoint for whether the company is executing on its promise.
For anyone tracking biopharma opportunities, Liquidia is a case study in how niche drug launches can attract fast institutional interest when early numbers exceed expectations. The company’s next moves on commercialization and the courtroom will determine whether this is a consolidation target, a sustainable specialty franchise, or a volatile biotech story. Disclosure: None. This is informational in nature and not investment advice.
